STAAR Surgical

Canaccord Genuity acts as Sole Bookrunning Manager for US$78.0 million bought deal public offering of common stock by STAAR Surgical Company

Canaccord Genuity is pleased to announce that on August 10, 2018, it completed a bought deal public offering of common stock for STAAR Surgical Company (NASDAQ: STAA) (the “Company”). The Company issued a total of 1,999,850 shares of its common stock at a price to the public of $39.00 per share, which includes the full exercise of the underwriters’ overallotment option. The gross proceeds to the Company, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately $78.0 million. The Company intends to use the net proceeds from the offering to advance and broaden commercialization of its ICL product line, fund pipeline R&D activities and clinical trials, fund manufacturing improvements and capital expenditures and for general corporate purposes, including working capital.

Canaccord Genuity acted as the Sole Bookrunning Manager for the offering.

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and companion delivery systems used to deliver its lenses into the eye. The Company offers implantable Collamer lenses and intraocular lenses used in the treatment of myopia (nearsightedness), hyperopia (farsightedness) and astigmatism. The Company’s goal is to position its refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing glasses or contact lenses while achieving excellent visual acuity through refractive vision correction.

Canaccord Genuity is focused on the corporate finance needs associated with growth companies in the United States, Canada, Europe and Asia. We are structured to provide our clients with a full range of global investment banking services, including corporate finance, research, sales and trading. Our thematic research focusing on companies around the world provides our firm with unique access to growth investors. In the last twelve months, the firm executed 190 public and private financings that raised approximately $19.2 billion and advised on 34 M&A assignments for approximately $3.2 billion.

We welcome the chance to work with you in the future, and please feel free to contact any of our team members if we can be of assistance.